ATRA Price / Book | ATARA BIOTHERAPEUTICS, INC.

Atara Biotherapeutics, Inc. Price/Book Ratio

The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.

Atara Biotherapeutics, Inc. price/book ratio for the quarter ending 2026-06-30 was -2.93, a change of -1.37 year-over-year.
Atara Biotherapeutics, Inc. price/book ratio for the quarter ending 2026-03-31 was -1.1, a change of -0.46 year-over-year.
Atara Biotherapeutics, Inc. price/book ratio for the quarter ending 2025-12-31 was -3.44, a change of -2.64 year-over-year.
Atara Biotherapeutics, Inc. price/book ratio for the quarter ending 2025-09-30 was -2.81, a change of -2.29 year-over-year.
Atara Biotherapeutics, Inc. price/book ratio for fiscal 2026 was -2.93.
Atara Biotherapeutics, Inc. price/book ratio for fiscal 2025 was -3.44, a change of -2.64 from fiscal 2024.
Atara Biotherapeutics, Inc. price/book ratio for fiscal 2024 was -0.8, a 245.66% decline from fiscal 2023.
Atara Biotherapeutics, Inc. price/book ratio for fiscal 2023 was 0.55, a 99.11% decline from fiscal 2022.

Available history: 2014-12-31 to 2026-06-30
Data captured: 2026-06-30

Historical Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	-2.93	$108.22M	-$37M
2026-03-31	-1.1	$41.11M	-$37.31M
2025-12-31	-3.44	$132.34M	-$38.5M
2025-09-30	-2.81	$102.81M	-$36.63M
2025-06-30	-1.55	$54.43M	-$35.04M
2025-03-31	-0.64	$35.19M	-$55.07M
2024-12-31	-0.8	$77.98M	-$97.28M
2024-09-30	-0.52	$46.67M	-$90.54M
2024-06-30	-0.38	$41.68M	-$110.87M
2024-03-31	-21.24	$2.09B	-$98.31M
2023-12-31	0.55	$54.61M	$99.23M
2023-09-30	-74.18	$3.77B	-$50.84M
2023-06-30	545.93	$4.07B	$7.45M
2023-03-31	107.74	$7B	$64.96M
2022-12-31	62.11	$7.87B	$126.64M
2022-09-30	47.92	$8.97B	$187.11M
2022-06-30	71.37	$18.38B	$257.48M
2022-03-31	96.71	$21.69B	$224.32M
2021-12-31	129.17	$36.12B	$279.61M
2021-09-30	127.53	$39.55B	$310.14M
2021-06-30	99.38	$32.95B	$331.54M
2021-03-31	75.64	$30.18B	$399.04M
2020-12-31	88.5	$40.91B	$462.34M
2020-09-30	70.69	$25.02B	$353.94M
2020-06-30	71.02	$27.07B	$381.13M
2020-03-31	49.6	$12.54B	$252.82M
2019-12-31	80.44	$23.39B	$290.78M
2019-09-30	60	$19.11B	$318.44M
2019-06-30	101.47	$23.57B	$232.28M
2019-03-31	162.07	$46.02B	$283.93M
2018-12-31	117.65	$39.91B	$339.22M
2018-09-30	117.07	$47.19B	$403.05M
2018-06-30	92.05	$41.65B	$452.5M
2018-03-31	97.44	$42.8B	$439.18M
2017-12-31	78.18	$13.91B	$177.86M
2017-09-30	0.06	$12.66M	$205.96M
2017-06-30	0.05	$10.47M	$221.14M
2017-03-31	0.06	$14.95M	$233.13M
2016-12-31	40.48	$10.27B	$253.74M
2016-09-30	57.08	$15.42B	$270.2M
2016-06-30	55.66	$16.15B	$290.25M
2016-03-31	44.76	$13.6B	$303.83M
2015-12-31	59.63	$18.79B	$315.1M
2015-09-30	66.71	$22.26B	$333.75M
2015-06-30	213.43	$31.86B	$149.26M
2015-03-31	149.62	$24.85B	$166.09M
2014-12-31	127.64	$13.17B	$103.18M

Annual Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	-2.93	$108.22M	-$37M
2025-12-31	-3.44	$132.34M	-$38.5M
2024-12-31	-0.8	$77.98M	-$97.28M
2023-12-31	0.55	$54.61M	$99.23M
2022-12-31	62.11	$7.87B	$126.64M
2021-12-31	129.17	$36.12B	$279.61M
2020-12-31	88.5	$40.91B	$462.34M
2019-12-31	80.44	$23.39B	$290.78M
2018-12-31	117.65	$39.91B	$339.22M
2017-12-31	78.18	$13.91B	$177.86M
2016-12-31	40.48	$10.27B	$253.74M
2015-12-31	59.63	$18.79B	$315.1M
2014-12-31	127.64	$13.17B	$103.18M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Pelthos Therapeutics Inc. (PTHS)	United States	$0.086B	-1.20
COGNITION THERAPEUTICS INC (CGTX)	United States	$0.090B	-6.52
Vaxart, Inc. (VXRT)	United States	$0.080B	3.84
Kalaris Therapeutics, Inc. (KLRS)	United States	$0.073B	-2.19
Cardiff Oncology, Inc. (CRDF)	United States	$0.101B	-2.22
CHAMPIONS ONCOLOGY, INC. (CSBR)	United States	$0.070B	-68.02
BioStem Technologies, Inc. (BSEM)	United States	$0.069B
Eloxx Pharmaceuticals, Inc. (ELOX)	United States	$0.065B
Black Diamond Therapeutics, Inc. (BDTX)	United States	$0.109B	-2.48
MiNK Therapeutics, Inc. (INKT)	United States	$0.063B	-5.37